Diffusion Pharmaceuticals Inc. [NASDAQ: DFFN] gained 12.85% or 0.09 points to close at $0.77 with a heavy trading volume of 4107730 shares. The company report on May 10, 2021 that Diffusion Pharmaceuticals Reports Final Results from Its Phase 1b Study of Trans Sodium Crocetinate in Hospitalized COVID-19 Patients.
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced final results from the Phase 1b study evaluating trans sodium crocetinate (TSC) in hospitalized COVID-19 patients. Data from the open-label study were reviewed by an independent Safety Monitoring Committee (SMC).
Topline results based upon analyses of primary endpoint data from the trial were announced in February 2021, indicating that TSC was safe and well-tolerated when administered on a more frequent dosing regimen than previously tested in a clinical trial setting.
It opened the trading session at $0.7079, the shares rose to $0.77 and dropped to $0.66, the range by which the price of stock traded the whole day. The daily chart for DFFN points out that the company has recorded -2.53% loss over the past six months. However, it is still -37.5% lower than its most recent low trading price.
If we look at the average trading volume of 6.99M shares, DFFN reached to a volume of 4107730 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Diffusion Pharmaceuticals Inc. [DFFN]:
H.C. Wainwright have made an estimate for Diffusion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 17, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on March 21, 2018, representing the official price target for Diffusion Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Diffusion Pharmaceuticals Inc. is set at 0.05 The Price to Book ratio for the last quarter was 2.03, with the Price to Cash per share for the same quarter was set at 0.18.
Trading performance analysis for DFFN stock
Diffusion Pharmaceuticals Inc. [DFFN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.91. With this latest performance, DFFN shares dropped by -8.66% in over the last four-week period, additionally sinking by -2.53% over the last 6 months – not to mention a rise of 26.27% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DFFN stock in for the last two-week period is set at 49.25, with the RSI for the last a single of trading hit 56.11, and the three-weeks RSI is set at 46.50 for Diffusion Pharmaceuticals Inc. [DFFN]. The present Moving Average for the last 50 days of trading for this stock 0.8628, while it was recorded at 0.7022 for the last single week of trading, and 0.9326 for the last 200 days.
Diffusion Pharmaceuticals Inc. [DFFN]: A deeper dive into fundamental analysis
Diffusion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.70 and a Current Ratio set at 7.70.
Diffusion Pharmaceuticals Inc. [DFFN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Diffusion Pharmaceuticals Inc. posted -0.07/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 12.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DFFN.
An analysis of insider ownership at Diffusion Pharmaceuticals Inc. [DFFN]
There are presently around $4 million, or 6.60% of DFFN stock, in the hands of institutional investors. The top three institutional holders of DFFN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 2,832,739, which is approximately -5.214% of the company’s market cap and around 0.13% of the total institutional ownership; BLACKROCK INC., holding 2,044,449 shares of the stock with an approximate value of $1.39 million in DFFN stocks shares; and VANGUARD GROUP INC, currently with $0.27 million in DFFN stock with ownership of nearly 11.624% of the company’s market capitalization.
10 institutional holders increased their position in Diffusion Pharmaceuticals Inc. [NASDAQ:DFFN] by around 1,568,496 shares. Additionally, 16 investors decreased positions by around 564,942 shares, while 4 investors held positions by with 4,003,283 shares. The mentioned changes placed institutional holdings at 6,136,721 shares, according to the latest SEC report filing. DFFN stock had 5 new institutional investments in for a total of 277,032 shares, while 11 institutional investors sold positions of 380,055 shares during the same period.